Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 12 Carcinoma, Non-Small-Cell Lung 9 Endometrial Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Ovarian Neoplasms 3 Melanoma 3 Head and Neck Neoplasms 3 Stomach Neoplasms 2 Rectal Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Rhabdomyosarcoma 1 Recurrence 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Neuroblastoma 1 Neoplasms by Site 1 Lung Neoplasms 1 Hodgkin Disease 1 Hepatoblastoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fibrolamellar hepatocellular carcinoma 1 Ependymoma 1 Digestive System Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡